Table 3.
No | Age/Sex | Clinical outcome at 12 Month | Tregs1 | Donor-specific lymphocyte proliferation2 | Donor-specific T cell proliferation3 | Cytokines4 |
---|---|---|---|---|---|---|
1 |
34/M |
Borderline change |
↑↑ |
↑ |
- |
IL-10 at D + 7 IL-6 at D + 7 |
2 |
48/F |
No AR |
↑↑ |
- |
- |
IL-10 at D + 30 |
3 |
40/M |
No AR |
- |
ND* |
ND* |
NC** |
4 |
32/F |
ACR |
- |
↑ |
↑↑ |
NC** |
5 |
36/M |
No AR |
- |
↓↓ |
↓↓ |
IL-6 at D + 7 IFN-γ at D + 30 |
6 |
36/F |
Borderline change |
- |
- |
- |
|
7 | 40/F | ACR | - | ↓ | ↓↓ | IFN-γ at D + 4 |
1Represented by the level of FoxP3mRNA : compared to baseline (D −35) control (Figure 1).
2Peripheral blood lymphocytes were co-cultured with donor cells (MLR) (Figure 2).
3ConA-induced T cell proliferation in the MLR system. (Figure 3).
4Cytokines their secretion was significantly increased compared to donor and baseline (D-35) level. (Figures 4, 5, 6).
*ND = Not detected: due to the lack of sample.
**NC = No changes.
↑ or ↓ = Increased or decreased values compared to baseline (D-35) control.